Teva gained nearly 2.5% in New York as Jefferies upgraded its recommendation on the stock from 'hold' to 'buy', with a price target raised from $10 to $14.

The anlayste is optimistic for 2024 'given that the earnings consensus looks conservative despite several favorable winds at work'.

'Overall, we believe that as Teva implements its growth strategy and transitions to an innovation-driven company, we expect to see multiples expand this year', adds the broker.

Copyright (c) 2024 CercleFinance.com. All rights reserved.